Gary Nachman
Stock Analyst at Canaccord Genuity
(3.58)
# 1,261
Out of 5,182 analysts
107
Total ratings
56.41%
Success rate
4.53%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Initiates: Buy | $262 | $198.71 | +31.85% | 18 | Apr 21, 2026 | |
| SRRK Scholar Rock Holding | Initiates: Buy | $62 | $46.48 | +33.39% | 6 | Apr 21, 2026 | |
| IONS Ionis Pharmaceuticals | Initiates: Buy | $110 | $73.27 | +50.13% | 5 | Apr 21, 2026 | |
| ADMA ADMA Biologics | Initiates: Buy | $21 | $11.26 | +86.50% | 1 | Apr 21, 2026 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $13 | $4.02 | +223.38% | 2 | Apr 21, 2026 | |
| AMGN Amgen | Initiates: Hold | $366 | $344.55 | +6.23% | 3 | Apr 21, 2026 | |
| BLCO Bausch + Lomb | Reiterates: Outperform | $18 → $19 | $15.82 | +20.10% | 2 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $9.38 | +433.05% | 3 | Oct 20, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $2.32 | +762.07% | 2 | Aug 13, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $11.79 | +137.49% | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $298 | $305.54 | -2.47% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $37 | $24.51 | +50.96% | 13 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $4.08 | +71.57% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $196.52 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $12.52 | -68.05% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $11.70 | +156.41% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $4.15 | +671.08% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $14.59 | -4.04% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $75 | $9.60 | +681.25% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $30.64 | -67.36% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $30.29 | -0.96% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $4.62 | +16,133.77% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $5.63 | +42.10% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $21.41 | -1.91% | 5 | May 11, 2020 |
AbbVie
Apr 21, 2026
Initiates: Buy
Price Target: $262
Current: $198.71
Upside: +31.85%
Scholar Rock Holding
Apr 21, 2026
Initiates: Buy
Price Target: $62
Current: $46.48
Upside: +33.39%
Ionis Pharmaceuticals
Apr 21, 2026
Initiates: Buy
Price Target: $110
Current: $73.27
Upside: +50.13%
ADMA Biologics
Apr 21, 2026
Initiates: Buy
Price Target: $21
Current: $11.26
Upside: +86.50%
Achieve Life Sciences
Apr 21, 2026
Initiates: Buy
Price Target: $13
Current: $4.02
Upside: +223.38%
Amgen
Apr 21, 2026
Initiates: Hold
Price Target: $366
Current: $344.55
Upside: +6.23%
Bausch + Lomb
Oct 30, 2025
Reiterates: Outperform
Price Target: $18 → $19
Current: $15.82
Upside: +20.10%
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $9.38
Upside: +433.05%
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $2.32
Upside: +762.07%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $11.79
Upside: +137.49%
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $305.54
Upside: -2.47%
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $24.51
Upside: +50.96%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $4.08
Upside: +71.57%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $196.52
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $12.52
Upside: -68.05%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $11.70
Upside: +156.41%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $4.15
Upside: +671.08%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $14.59
Upside: -4.04%
Nov 14, 2022
Maintains: Outperform
Price Target: $90 → $75
Current: $9.60
Upside: +681.25%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $30.64
Upside: -67.36%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $30.29
Upside: -0.96%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $4.62
Upside: +16,133.77%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $5.63
Upside: +42.10%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $21.41
Upside: -1.91%